The United States and the United Kingdom finalized a landmark pharmaceutical pricing and trade agreement that will increase the net price the NHS pays for new patented medicines and reduce rebates for pharmaceutical companies.Under the deal, the U.S. will exempt U.K.-made pharmaceuticals from Section 232 tariffs and guarantee zero-tariff access to American markets, while President Donald Trump pledged not to pursue British pricing practices in future Section 301 investigations.Key figures including Ambassador
Jamieson Greer,
Howard Lutnick,
Robert F. Kennedy Jr., President
Donald Trump, and Prime Minister
Keir Starmer emphasized the agreement’s impact on research investment, innovation, and rebalancing drug pricing across peer countries.